MABVAX THERAPEUTICS HOLDINGS, INC. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2013 12 months to Dec 31, 2013	FY2012 12 months to Dec 31, 2012
Revenues:
Grants
Other
Total revenues
Operating costs and expenses:
Research and development
General and administrative
Total operating costs and expenses
Loss from operations
Interest and other income, net
Interest expense
Interest and other expenses, net of income
Change in fair value of warrant liability
Net loss
Deemed dividend on Series A-1 preferred stock
Deemed dividend on Series A-1 warrant
Deemed dividend on Series B preferred stock
Deemed dividend on May 2017 inducement shares
Deemed dividend on August 2017 inducement shares
Deemed dividend on warrant repricing
Deemed dividend on preferred stock exchange
Accretion of preferred stock dividends
Net loss allocable to common stockholders
Basic and diluted net loss per share
Shares used to calculate basic and diluted net loss per share

Comments